OccuLogix, Inc.
NASDAQ : RHEO
TSX : RHE

OccuLogix, Inc.

June 07, 2005 12:50 ET

OccuLogix, Inc.: RHEO'TM' Mechanism of Action Article Published in the Canadian Journal of Ophthalmology

TORONTO, ONTARIO--(CCNMatthews - June 7, 2005) - OccuLogix, Inc. (NASDAQ:RHEO)(TSX:RHE) today announced that a peer-reviewed article entitled "Rheopheresis for Age-related Macular Degeneration: Clinical Results and Putative Mechanism of Action" has been published in the June 2005 issue (Volume 40, No. 3) of the Canadian Journal of Ophthalmology ("CJO").

The article can be accessed on the internet at http://pubs.nrc-cnrc.gc.ca/cjo/cjo40/i05-010.pdf or by visiting the "Clinical Studies" link in the Resource Library section of http://www.rheo.com.

The CJO is the official journal of the Canadian Ophthalmological Society. In 2005, the CJO enters its 40th year of publication. The CJO is the only peer-reviewed ophthalmology journal in Canada. It is written by the specialists for the specialists with findings not only from Canada, but from around the world.

About OccuLogix, Inc.

OccuLogix is a health care company that brings innovative and evidenced-based medical therapies to market. OccuLogix's common shares trade on the NASDAQ National Market under the symbol 'RHEO' and on the Toronto Stock Exchange under the symbol 'RHE'.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian regulatory authorities, including our Registration Statement on Form S-1. We do not undertake to update any forward-looking statements.

Contact Information